Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.1073479
Keywords
plasma cell dyscrasias; serum; M-protein; MALDI-TOF-MS; screening test
Categories
Funding
- National Natural Science Foundation of China [82104216]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515011450]
- Shenzhen Project of Science and Technology [JCYJ20190809094007719, JCYJ20190809095203586]
- fund of Sanming Project of Medicine in Shenzhen, China [SZSM201812088]
Ask authors/readers for more resources
A new MALDI-TOF Mass spectrometry-based method has been developed for rapid screening of M-proteins in human serum, showing high analytical performance and throughput as a new choice for the diagnosis of plasma cell dyscrasias.
Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
